JPWO2021014428A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2021014428A5
JPWO2021014428A5 JP2022504139A JP2022504139A JPWO2021014428A5 JP WO2021014428 A5 JPWO2021014428 A5 JP WO2021014428A5 JP 2022504139 A JP2022504139 A JP 2022504139A JP 2022504139 A JP2022504139 A JP 2022504139A JP WO2021014428 A5 JPWO2021014428 A5 JP WO2021014428A5
Authority
JP
Japan
Prior art keywords
nucleic acid
seq
acid molecule
exon
optionally
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022504139A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022541070A (ja
JP2022541070A5 (https=
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2020/057038 external-priority patent/WO2021014428A1/en
Publication of JP2022541070A publication Critical patent/JP2022541070A/ja
Publication of JPWO2021014428A5 publication Critical patent/JPWO2021014428A5/ja
Publication of JP2022541070A5 publication Critical patent/JP2022541070A5/ja
Priority to JP2025013522A priority Critical patent/JP2025069281A/ja
Withdrawn legal-status Critical Current

Links

JP2022504139A 2019-07-25 2020-07-24 調節可能な発現系 Withdrawn JP2022541070A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025013522A JP2025069281A (ja) 2019-07-25 2025-01-30 調節可能な発現系

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962878514P 2019-07-25 2019-07-25
US62/878,514 2019-07-25
US202063013283P 2020-04-21 2020-04-21
US63/013,283 2020-04-21
PCT/IB2020/057038 WO2021014428A1 (en) 2019-07-25 2020-07-24 Regulatable expression systems

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025013522A Division JP2025069281A (ja) 2019-07-25 2025-01-30 調節可能な発現系

Publications (3)

Publication Number Publication Date
JP2022541070A JP2022541070A (ja) 2022-09-21
JPWO2021014428A5 true JPWO2021014428A5 (https=) 2023-08-01
JP2022541070A5 JP2022541070A5 (https=) 2023-08-01

Family

ID=71944162

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022504139A Withdrawn JP2022541070A (ja) 2019-07-25 2020-07-24 調節可能な発現系
JP2025013522A Pending JP2025069281A (ja) 2019-07-25 2025-01-30 調節可能な発現系

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025013522A Pending JP2025069281A (ja) 2019-07-25 2025-01-30 調節可能な発現系

Country Status (9)

Country Link
US (1) US20220307053A1 (https=)
EP (1) EP4004213A1 (https=)
JP (2) JP2022541070A (https=)
KR (1) KR20220035937A (https=)
CN (2) CN114174514A (https=)
AU (1) AU2020319168B2 (https=)
CA (1) CA3147574A1 (https=)
IL (1) IL289711A (https=)
WO (1) WO2021014428A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4103717A4 (en) * 2020-02-12 2024-02-28 The Children's Hospital of Philadelphia COMPOSITIONS AND METHODS FOR INDUCIBLE ALTERNATIVE SPLICING REGULATION OF GENE EXPRESSION
WO2022226183A2 (en) * 2021-04-21 2022-10-27 The Board Of Regents Of The University Of Texas System Optimized ap4m1 polynucleotides and expression cassettes and their use
GB2617565A (en) * 2022-04-11 2023-10-18 Ucl Business Ltd A construct, vector and system and uses thereof
WO2023219533A1 (ru) * 2022-05-11 2023-11-16 Общество С Ограниченной Ответственностью "Герофарм" Аденоассоциированный вирусный вектор на основе серотипа aav.php.b и его применение
CN118339290A (zh) * 2022-09-23 2024-07-12 北京基驭医疗科技有限公司 包含基于小分子药物的可变剪接调节元件的核酸分子
GB202215198D0 (en) * 2022-10-14 2022-11-30 Univ Sheffield Gene therapy treatment
EP4677098A1 (en) * 2023-03-06 2026-01-14 Agency for Science, Technology and Research Engineered furin cleavage sequences for co-expression of multiple genes in mammalian cells
KR20260003718A (ko) * 2023-04-14 2026-01-07 알젠타 테라퓨틱스, 인크. 소분자 조절 대체 스플라이싱
WO2025015060A1 (en) * 2023-07-11 2025-01-16 Brave Bio, Inc. Engineered vectorized antibodies with reduced stability in systemic circulation and uses thereof

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
US5173414A (en) 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
PT733103E (pt) 1993-11-09 2004-07-30 Targeted Genetics Corp Criacao de elevados titulos de vectores de aav recombinantes
PT728214E (pt) 1993-11-09 2004-11-30 Ohio Med College Linhas celulares estaveis capazes de expressar o gene de replicacao do virus adeno-associado
US5658785A (en) 1994-06-06 1997-08-19 Children's Hospital, Inc. Adeno-associated virus materials and methods
US5856152A (en) 1994-10-28 1999-01-05 The Trustees Of The University Of Pennsylvania Hybrid adenovirus-AAV vector and methods of use therefor
AU707866B2 (en) 1994-12-06 1999-07-22 Targeted Genetics Corporation Packaging cell lines for generation of high titers of recombinant AAV vectors
US6001650A (en) 1995-08-03 1999-12-14 Avigen, Inc. High-efficiency wild-type-free AAV helper functions
FR2737730B1 (fr) 1995-08-10 1997-09-05 Pasteur Merieux Serums Vacc Procede de purification de virus par chromatographie
AU722196B2 (en) 1995-08-30 2000-07-27 Genzyme Corporation Chromatographic purification of adenovirus and AAV
EP1983057A3 (en) 1995-09-08 2009-01-07 Genzyme Corporation Improved AAV vectors for gene therapy
US5910434A (en) 1995-12-15 1999-06-08 Systemix, Inc. Method for obtaining retroviral packaging cell lines producing high transducing efficiency retroviral supernatant
JP2001514845A (ja) 1997-09-05 2001-09-18 ターゲティッド ジェネティクス コーポレイション 組換えaavベクターの高力価ヘルパーなし調製物を生成するための方法
US6410300B1 (en) 1998-01-12 2002-06-25 The University Of North Carolina At Chapel Hill Methods and formulations for mediating adeno-associated virus (AAV) attachment and infection and methods for purifying AAV
US6258595B1 (en) 1999-03-18 2001-07-10 The Trustees Of The University Of Pennsylvania Compositions and methods for helper-free production of recombinant adeno-associated viruses
CA2406743A1 (en) 2000-04-28 2001-11-08 The Trustees Of The University Of Pennsylvania Recombinant aav vectors with aav5 capsids and aav5 vectors pseudotyped in heterologous capsids
US9441244B2 (en) 2003-06-30 2016-09-13 The Regents Of The University Of California Mutant adeno-associated virus virions and methods of use thereof
US9233131B2 (en) 2003-06-30 2016-01-12 The Regents Of The University Of California Mutant adeno-associated virus virions and methods of use thereof
EP1751275B1 (en) 2004-06-01 2017-08-16 Avigen, Inc. Compositions and methods to prevent aav vector aggregation
US8110681B2 (en) 2006-03-17 2012-02-07 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Compounds for the treatment of spinal muscular atrophy and other uses
CA2653974A1 (en) 2006-05-30 2008-02-14 Mayo Foundation For Medical Education And Research Detecting and treating dementia
WO2009151546A2 (en) * 2008-05-27 2009-12-17 Ptc Therapeutics, Inc. Methods for treating spinal muscular atrophy
DK2529020T3 (en) 2010-01-28 2018-08-06 Childrens Hospital Philadelphia SCALABLE PREPARATION PLATF FOR CLEANING VIRAL VECTORS AND CLEANED VIRAL VECTORS FOR USE IN GENTHERAPY
DE102012007232B4 (de) 2012-04-07 2014-03-13 Susanne Weller Verfahren zur Herstellung von rotierenden elektrischen Maschinen
US8729263B2 (en) 2012-08-13 2014-05-20 Novartis Ag 1,4-disubstituted pyridazine analogs there of and methods for treating SMN-deficiency-related conditions
US9040712B2 (en) 2013-01-23 2015-05-26 Novartis Ag Thiadiazole analogs thereof and methods for treating SMN-deficiency-related-conditions
EP4105208A1 (en) 2013-07-31 2022-12-21 Novartis AG 1,4-disubstituted pyridazine derivatives and their use for treating smn-deficiency-related conditions
JP2015092462A (ja) 2013-09-30 2015-05-14 Tdk株式会社 正極及びそれを用いたリチウムイオン二次電池
US10183065B2 (en) * 2013-10-28 2019-01-22 Invectys Telomerase encoding DNA vaccine
JP6202701B2 (ja) 2014-03-21 2017-09-27 株式会社日立国際電気 基板処理装置、半導体装置の製造方法及びプログラム
WO2016034680A1 (en) * 2014-09-05 2016-03-10 Stichting Katholieke Universiteit Antisense oligonucleotides for the treatment of leber congenital amaurosis
JP6197169B2 (ja) 2014-09-29 2017-09-20 東芝メモリ株式会社 半導体装置の製造方法
EA201800367A1 (ru) 2015-12-10 2019-02-28 ПиТиСи ТЕРАПЬЮТИКС, ИНК. Способы лечения болезни хантингтона
US11655470B2 (en) * 2016-07-05 2023-05-23 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Diagnosing COL6-related disorders and methods for treating same
JP2019535789A (ja) 2016-11-28 2019-12-12 ピーティーシー セラピューティクス,インコーポレーテッド Rnaスプライシングを調節する方法
EP3634953B1 (en) 2017-06-05 2024-01-03 PTC Therapeutics, Inc. Compounds for treating huntington's disease
JP2020523365A (ja) * 2017-06-14 2020-08-06 ピーティーシー セラピューティクス,インコーポレーテッド Rnaスプライシングを改変する方法
MX2019015580A (es) 2017-06-28 2020-07-28 Ptc Therapeutics Inc Metodos para tratar la enfermedad de huntington.
CN111182898B (zh) 2017-06-28 2024-04-16 Ptc医疗公司 用于治疗亨廷顿氏病的方法
JP7312749B2 (ja) 2017-08-04 2023-07-21 スカイホーク・セラピューティクス・インコーポレーテッド スプライシングをモジュレートする方法および組成物
MX2020004830A (es) 2017-11-08 2020-11-11 Avexis Inc Medios y metodo para preparar vectores virales y usos de los mismos.

Similar Documents

Publication Publication Date Title
US11344608B2 (en) Factor IX gene therapy
JP2021512649A5 (https=)
JP2021532812A5 (https=)
JPWO2020106916A5 (https=)
US20200370069A1 (en) Treatment of spinal muscular atrophy
RU2021102893A (ru) Модифицированные гены атаксии фридрейха и векторы для генной терапии
JP7541027B2 (ja) 筋肉発現のためのハイブリッドプロモーター
KR20210096168A (ko) 신경퇴행성 질환을 위한 유전자 요법
JP2021520811A5 (https=)
JP2023065516A5 (https=)
JPWO2021014428A5 (https=)
JPWO2019153009A5 (https=)
CA3122319A1 (en) Expression cassettes for gene therapy vectors
JP2021534766A5 (https=)
CN120548368A (zh) 用于正确包装重复元件的腺相关病毒载体
JPWO2020232297A5 (https=)
JPWO2021108809A5 (https=)
CN121358754A (zh) 具有外周器官去靶向性的新型嗜神经性腺相关病毒衣壳
JP2025515356A5 (https=)
EP4602055A1 (en) Hybrid aav vector enhancing transgene expression in the liver
JP2024517957A (ja) ベクター系
JPWO2021076911A5 (https=)
JPWO2022034130A5 (https=)
JPWO2020237130A5 (https=)
RU2025132907A (ru) Нуклеиновая кислота, кодирующая белок, специфичный к vegf, полинуклеотидная кассета экспрессии и рекомбинантный аденоассоциированный вирус